Sunday, September 27, 2020

Tag: Neuralstem

Stem Cell-Based Phase I Trial to Repair Spinal Cord Injuries Produces Encouraging Results

Published: June 1, 2018 | Spinal Cord Injury: , , , , , , , , , ,

First-in-human clinical study found improved motor and sensory function in three of four participants

Writing in the June 1 issue of Cell Stem Cell, researchers at University of California San Diego School of Medicine report that a first-in-human phase I clinical trial in which neural stem cells were transplanted into participants with chronic spinal cord injuries produced measurable improvement in three of four subjects, with no serious adverse effects.

The Race To Treat Spinal Cord Injury: A Comparative Analysis

Published: July 16, 2015

Summary

  • Four biotech companies are pursuing the treatment of spinal cord injury with the use of stem cell transplantation.
  • Each company demonstrated efficacy in pre-clinical studies.
  • The race is in the early stages but InVivo Therapeutics is clearly leading the pack based on its strategic approach to accelerated HDE approval and initial trial results.

Neuralstem spinal cord injury stem cell trial approved to commence at University Of California

Published: April 18, 2014 | Spinal Cord Injury: ,

Neuralstem LogoNeuralstem, announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI phase I trial will enroll patients with thoracic spinal cord injuries (T2-T12) who have an American Spinal Injury Association (AIS) A level of impairment, between one and two years after injury. AIS A impairment, which is complete paralysis, refers to a patient with no motor or sensory function in the relevant segments at and below the injury.